Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

3.7K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.7K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:22

Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.8K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
1.8K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

823
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
823
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.5K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.5K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

2.6K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.6K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

3.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
3.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thia-Michael Stapling of Allenamide-Incorporated α-Helical Antimicrobial Peptides.

The Journal of organic chemistry·2026
Same author

Synthesis of the Antifungal and Antiviral Cyclic Lipodepsipeptides Verlamelins A and B.

The Journal of organic chemistry·2026
Same author

Introducing CLipPA lipid chemodiversity to enzymatically truncated polymyxin B: a soft drug strategy to combat Gram-negative pathogens.

RSC medicinal chemistry·2026
Same author

Broad-Spectrum Peptidomimetic Inhibitors of Norovirus and Coronavirus 3C-like Proteases.

ACS infectious diseases·2025
Same author

Design, synthesis and biological activity of potential retrometabolic polymyxins <i>via</i> thiol-ene chemistry.

Chemical communications (Cambridge, England)·2025
Same author

Beyond the "2 + 2 Pharmacophore" Electronic and Hydrophobic Effects Control the Activity of Cationic Amphiphilic Antimicrobial 2,5-Diketopiperazines.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: Dec 17, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

TLR2 agonists and their structure-activity relationships.

Benjamin L Lu1, Geoffrey M Williams1, Margaret A Brimble1

  • 1The School of Biological Sciences, University of Auckland, 3A Symonds St, Auckland 1010, New Zealand. m.brimble@auckland.ac.nz and The School of Chemical Sciences, University of Auckland, 23 Symonds St, Auckland 1010, New Zealand and Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland 1010, New Zealand.

Organic & Biomolecular Chemistry
|June 26, 2020
PubMed
Summary
This summary is machine-generated.

Synthetic Toll-like Receptor 2 (TLR2) agonists are crucial for cancer immunotherapy adjuvants. Understanding their structure-activity relationships aids in designing effective vaccines targeting the TLR2 pathway.

More Related Videos

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.8K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 17, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K
Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography
09:09

Preparation and Delivery of Protein Microcrystals in Lipidic Cubic Phase for Serial Femtosecond Crystallography

Published on: September 20, 2016

11.8K
Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation
16:02

Demonstration of the Sequence Alignment to Predict Across Species Susceptibility Tool for Rapid Assessment of Protein Conservation

Published on: February 10, 2023

3.1K

Area of Science:

  • Immunology and Medicinal Chemistry
  • Focuses on synthetic agonists for Toll-like Receptor 2 (TLR2).
  • Explores applications in immunotherapy and vaccine development.

Background:

  • Toll-like Receptor 2 (TLR2) agonists are valuable as vaccine adjuvants.
  • Their role in immunotherapy for diseases like cancer is significant.
  • A deep understanding of structure-activity relationships (SAR) is needed for rational drug design.

Purpose of the Study:

  • To review and synthesize existing literature on synthetic TLR2 agonists.
  • To discuss the structure-activity relationships of these compounds.
  • To provide a comprehensive overview for researchers in the field.

Main Methods:

  • Literature review and collation of synthetic studies.
  • Analysis of structure-activity relationships reported in the literature.
  • Discussion of findings to identify trends and knowledge gaps.

Main Results:

  • Identified various synthetic strategies for TLR2 agonists.
  • Detailed SAR studies highlighting key structural features for TLR2 activation.
  • Summarized the potential of TLR2 agonists in different therapeutic contexts.

Conclusions:

  • Synthetic TLR2 agonists hold significant promise for vaccine development and immunotherapy.
  • Further research into SAR is essential for optimizing agonist design.
  • This review provides a foundation for future efforts in discovering potent TLR2 agonists.